中文网站
Recently, a biotechnology company from India paid a special visit to the production base of Hangzhou Bigfexu Biotechnology Co., Ltd. to conduct an on-site inspection of the company’s R&D, manufacturing, and product systems. The visit served as a bridge for communication and laid the foundation for future collaboration between both parties in the field of life sciences.
As a professional local supplier in India specializing in biotechnology products, the company focuses on sectors including immunoassays (ELISA), biochemical testing, antibodies, recombinant proteins, molecular biology products, and cell culture products. With business operations covering South Asia and neighboring regional markets, it is considered one of the key service providers in the local medical diagnostics industry chain.
Accompanied by the overseas and marketing departments of Bigfexu, the Indian delegation toured the company’s GMP-compliant production workshops and molecular diagnostics R&D center. They gained a thorough understanding of the production processes and quality control standards for core products such as nucleic acid extraction instruments, PCR instruments, and real-time fluorescence PCR systems, as well as the technical strengths of the products—including high integration and miniaturization, a high degree of automation, and intelligent software.
During the visit, both sides engaged in in-depth and focused discussions on topics such as adapting product performance to the needs of primary healthcare and laboratory scenarios in South Asia, and establishing a localized technical support system.
By the fourth quarter of this year, Bigfexu had already established stable partnerships with several key regional distributors in India. Its products have been deployed across primary healthcare institutions and clinical laboratories in major Indian cities. Due to their suitability for operational needs in primary medical settings, the company’s compact nucleic acid extractors and automated PCR testing devices have become widely used equipment for infectious disease screening and basic disease diagnosis in the region.
During the discussions, the Indian partners noted that Bigfexu’s technological capabilities and standardized manufacturing fully align with the South Asian market’s demand for efficient and user-friendly diagnostic devices. They expressed strong expectations for further cooperation to bring more high-quality products into India and neighboring regional markets.
Bigfexu’s overseas representative emphasized that India is a core market within the company’s strategic layout for South Asia. Existing collaborations have already demonstrated strong compatibility between Bigfexu’s products and local market needs. At the same time, the partner’s channel resources and industry expertise in South Asia are highly complementary to the company’s global expansion strategy. The on-site visit has facilitated accurate alignment between both sides’ market needs. Moving forward, the parties will explore diverse cooperation models—such as agency partnerships and localized service solutions—leveraging the synergy between advanced product technologies and regional distribution networks to jointly accelerate the adoption of high-quality diagnostic products across the South Asian market.
This on-site visit marks an important milestone in Bigfexu’s efforts to deepen medical cooperation in the Indian market.
Moving forward, the company will continue to place product technology at its core and rely on localized partnership networks to help enhance the efficiency and capability of India’s primary healthcare diagnostic system.
Post time: Dec-04-2025
Privacy settings